An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cartesian Therapeutics, a clinical-stage biotechnology company, will present twelve-month follow-up data from its Phase 2a trial of Descartes-08 at the ASGCT 27th Annual Meeting. Descartes-08 is an autologous anti-BCMA mRNA-engineered CAR T-cell therapy for autoimmune diseases.
Cartesian Therapeutics, un'azienda biotecnologica in fase clinica, presenterà i dati di follow-up di dodici mesi dal suo studio di Fase 2a su Descartes-08 durante il 27° Incontro Annuale dell'ASGCT. Descartes-08 è una terapia CAR T-cellulare autologa anti-BCMA, ingegnerizzata con mRNA, per le malattie autoimmuni.
Cartesian Therapeutics, una empresa biotecnológica en etapa clínica, presentará los datos de seguimiento de doce meses de su ensayo de Fase 2a de Descartes-08 en la 27ª Reunión Anual de la ASGCT. Descartes-08 es una terapia con células CAR T autólogas anti-BCMA, diseñadas con mRNA, para enfermedades autoinmunes.
임상 단계에 있는 생명공학 회사인 카르테시안 테라퓨틱스는 자사의 2a상 시험에서의 데카르트-08의 12개월 추적 관찰 데이터를 ASGCT의 제27회 연례 회의에서 발표할 예정입니다. 데카르트-08은 자가면역 질환을 위한 자가 항-BCMA mRNA 공학화 CAR T-세포 치료법입니다.
Cartesian Therapeutics, une entreprise de biotechnologie en phase clinique, présentera les données de suivi de douze mois de son essai de phase 2a sur Descartes-08 lors de la 27ème réunion annuelle de l'ASGCT. Descartes-08 est une thérapie par cellules CAR T autologues anti-BCMA, conçue avec de l'ARNm, pour les maladies auto-immunes.
Cartesian Therapeutics, ein biotechnologisches Unternehmen in der klinischen Phase, wird Zwölf-Monate-Follow-Up-Daten aus seiner Phase-2a-Studie von Descartes-08 auf dem 27. Jahresmeeting der ASGCT präsentieren. Descartes-08 ist eine autologe anti-BCMA mRNA-engineered CAR T-Zelltherapie für Autoimmunerkrankungen.
Positive
None.
Negative
None.
GAITHERSBURG, Md.--(BUSINESS WIRE)--
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024 in Baltimore, MD. Descartes-08, the Company’s lead product candidate, is an autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T).
Details of the presentation are as follows:
Abstract Number: 241
Title: Investigation of mRNA Cell Therapy as a Treatment for Autoimmune Disease in Patients with Myasthenia Gravis
Session Title: Cell Therapy and Cell-Based Gene Therapy Trials
Session Date/Time: Friday May 10, 2024, 1:30-3:15 p.m. E.T.
Presentation Time: 1:45-2:00 p.m. E.T.
Room: Ballroom 1
A copy of the abstract is available through the ASGCT conference website.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
What is Cartesian Therapeutics presenting at the ASGCT 27th Annual Meeting?
Cartesian Therapeutics will present twelve-month follow-up data from its Phase 2a trial of Descartes-08, an autologous anti-BCMA mRNA-engineered CAR T-cell therapy for patients with generalized myasthenia gravis.
What is the lead product candidate of Cartesian Therapeutics?
The lead product candidate of Cartesian Therapeutics is Descartes-08, an autologous anti-BCMA mRNA-engineered CAR T-cell therapy for autoimmune diseases.
When and where will the presentation take place?
The presentation will be held at the ASGCT 27th Annual Meeting on Friday, May 10, 2024, from 1:45-2:00 p.m. E.T. in Ballroom 1.
What is the session title for Cartesian Therapeutics' presentation?
The session title for Cartesian Therapeutics' presentation is 'Investigation of mRNA Cell Therapy as a Treatment for Autoimmune Disease in Patients with Myasthenia Gravis'.
Where can the abstract of the presentation be found?
A copy of the abstract can be accessed through the ASGCT conference website.
